Sarah Howell, Ph.D, CEO
Dr. Howell has a strong background in clinical and commercial pharmaceutical product development, manufacture, supply and licensing across a range of product types and therapeutic areas having served in a number of leading roles in the pharmaceutical industry, most recently as Vice President for CMC (Chemistry, Manufacturing & Controls) and Technical Development for BTG where she had full responsibility for CMC development and supply across BTG’s diverse portfolio of clinical and commercial products. Previously she held senior roles in product development and manufacturing for UCB-Celltech and GlaxoSmithKline. She is also an active member of the BioIndustry Association (BIA) Manufacturing Advisory Committee. Dr. Howell has an honours degree in Chemistry from the University of Birmingham and a PhD in Physical Organic Chemistry from the University of St Andrews.
Jan Jezek, Ph.D, Chief Scientific Officer
Jan Jezek, the principal inventor of the core protein stabilisation technologies, is a biochemist with a strong background in physical chemistry.
Currently responsible for R&D activities, platform development and technical IP support in the field of stabilisation of biologics.
Played a crucial role in the development of stabilising technologies for commercially important proteins that allow preservation of protein structure and biological activity during sterilisation by gamma radiation and during long-term storage at ambient temperature.
Lead successful grant funded projects with TSB funding. Previously a Principal Scientist at Insense Limited, responsible for development of novel medical devices from concept to market. Holds a joint Doctorate from the University of Bedfordshire and the University of Chemical technology, Prague.
Member of the Scientific Advisory Board of the Centre of Excellence in Biopharmaceuticals (University of Manchester).
A Committee member of the Formulation Science & Technology Group (FSTG) at the Royal Society of Chemistry.
David Gerring, Head of Development
David Gerring has 15 years experience in pharmaceutical product and analytical development, as well as significant regulatory and quality experience including: Senior roles at Immunocore and Emmergent BioSolutions, 5 years at UCB in scientific and regulatory with a focus on the development and successful licensure of Cimzia, as well as heading up process and analytical development at BTG, managing CMC for several recombinant products including successful INDs and licensures. Head of development and operations at Arecor with responsibilties for scientific strategy, project management, facilities, health & safety, quality and client, grant and internal product development management.